Armata Q2 operating loss $11.9M; AP-PA02 Phase 2 enrollment complete, topline H2 2024

Armata Pharmaceuticals, Inc.

2024-Q2 EPS reported -$0.45

Q2 2024 operating loss $11.9M vs $9.6M in Q2 2023; R&D $8.5M, G&A $3.4M.
Cash and equivalents $26.4M as of June 30, 2024, up from $13.5M at Dec 31, 2023.
Completed enrollment in Phase 2 Tailwind study of inhaled AP-PA02; last patient visit Aug 7, topline data expected H2 2024.
Received $5.25M non-dilutive DoD grant for AP-SA02 diSArm Phase 2a study.
Built out cGMP manufacturing facility with five clean rooms, including fill-and-finish suite.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.